Roche opens €90m gene therapy development centre
Basel-headquartered Roche AG has inaugurated a brand new €90m gene therapy development centre in Penzberg near Munich. <br /><br /><br />
AstraZeneca to take over Fusion Therapeutics Inc
British pharma giant AstraZeneca has announced to acquire radio-conjugate specialist Fusion Therapeutics Inc for US$2bn upfront.
Senisca Ltd raises £3.7m seed money
Exeter-based university spin-out Senisca Ltd has added £3.7m seed money to a £1.1m not dilutive funding to advance its pipeline of drugs targetting RNA splicing dysregulation.
AstraZeneca to acquire Amolyt Pharma for up to US$1.05bn
French endocrine diseases specialist Amolyt Pharma SA has entered into a take-over agreement by AstraZeneca.
Relation Therapeutics Ltd bags US$35m in seed financing.
London-based virtual drug discovery specialist Relation Therapeutics Ltd has closed another US$35m seed financing round, bringing its total seed fundraise to US$60m.
Researcher find potential target for atherosclerosis
TREM2, a receptor on the surface of macrophages, reduces necrotic core formation in early atherosclerosis, a German-Austrian reseach team reports.
Obesity: Arecor Therapeutics partners with TRx Biosciences
British companies Arecor Therapeutics plc and TRx Biosciences Ltd combine their technologies to formulate an oral GLP-1 receptor agonist with enhanced bioavailability<br />
Scientist create non-digestible aptamer
German researchers for the first time have expanded the half life of oligonucleotide-based drugs using artificial building blocks that mimic the features of RNA/DNA but are not digestible by enzymes.
Scientists create non-digestible aptamer
German researchers for the first time have expanded the half life of oligonucleotide-based drugs using artificial building blocks that mimic the features of RNA/DNA but are not digestible by enzymes.
SynaptixBio Ltd gets FDA ODD for leukodystrophy
Rare disease specialist SynaptixBio Ltd has got its second FDA orphan drug designation for a subtype of TUBB4A leukodystrophy.